Drug intelligence / Profile preview

VTX-ID57

Development stage: Preclinical
Lead developer: Voltron Therapeutics
Modality: Vaccines & Immunotherapeutics

Overview

VTX-ID57 is an early-stage vaccine candidate being developed by Voltron Therapeutics for the prevention of poxvirus infections, specifically targeting the Vaccinia virus. The program is currently in the discovery phase and is supported by government funding. While specific details regarding the vaccine's platform technology or molecular targets have not been publicly disclosed, it is part of Voltron's infectious disease pipeline, which focuses on rapid vaccine development for emerging and established viral threats.

Beyond the preview

Go deeper on VTX-ID57.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VTX-ID57.

Explore the full profile